for over 1,000 Life Science Research Reports spanning over 50 Research Areas

Just some of the Reports Available Include:

- Alzheimer's Disease
- Biomarkers & Diagnostics
- BioPharma Strategy
- Biosimilars & Generic Markets
- Cancer Research and Therapeutics
- Chemistry
- Clinical Trials & Translational Medicine
- Data Mining
- Drug Discovery & Development
- Health IT

- Infectious Disease
- Medical Devices
- Multiple Sclerosis
- Ocular Therapeutics
- Pain Management
- Pharmaceutical Marketing
- Sequencing
- Vaccines

...and many others

InsightPharmaReports.com
An Essential Collection of Timely & Concise Reports Analyzing the Technologies, Markets, and Strategic Issues Driving R&D Productivity …. 

Insight Pharma Reports has been a report leader for over 15 years, and continues to deliver high quality data and findings. Our reports offer a comprehensive analysis of the drug discovery and development market, offering over 50 topic areas of research reports. All propriety reports that Insight Pharma Reports publishes are complete with in-depth interviews with senior level research executives and include extensive survey data. On average each report has insights from over 100 topic experts.

Also, available through Insight Pharma Reports and our network of Affiliated Reports, we offer over 1000 scientific research reports, with new reports being added weekly. However, if you can’t find a topic on what you are looking for, contact us, we can help you find a relevant report that fits your needs from our network of report publishers.

Contact Us:
Academic, Government and Non-Profit Discounts are available on most reports. We offer multi-report discounts as well.
For more information on discounts and up-to-date pricing, contact Daniel Miller at: DMiller@healthtech.com or call (781) 972-5492
# The Development of Therapeutic Monoclonal Antibody Products

The Development of Therapeutic Monoclonal Antibodies Second Edition goes beyond other reports by incorporating the latest technical developments and integrating strategic and regulatory considerations with these technical requirements. This report will serve as a guide to product development companies, service providers, investors, and analyst as they work their way through the complex and rapidly evolving world of therapeutic monoclonal antibodies.

[Insightpharmareports.com/Therapeutic-Monoclonal-Antibodies/](http://Insightpharmareports.com/Therapeutic-Monoclonal-Antibodies/)

## Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes

This new report builds on our 2014 Insight Pharma Report, Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies. In that report, we focused on the major classes of cancer immunotherapy drugs that were then emerging from academic and corporate research: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies. This new report includes an updated discussion of approved and clinical stage agents in immuno-oncology, including recently-approved agents. It also addresses the means by which researchers and companies are attempting to build on prior achievements in immuno-oncology to improve outcomes for more patients.


## Commercializing Novel IVDs: A Comprehensive Manual for Success

The process of developing a successful in vitro diagnostic (IVD) relies on the expertise of a diverse group of individuals, including the scientists who identify the biomarkers of significance, engineers and assay developers who translate those ideas into a tangible product, and the sales and marketing staff who get the product into the market. This unique manual will provide an overview of the major components to IVD development, from product conception through commercialization, and important considerations about individual aspects of the process including:

- How do I approach the regulatory process?
- How can I plan for market access, and what can I do to make sure my IVD will be reimbursed?


## Combination Antibody Therapy for Cancer Treatment Overview

Recombinant antibodies have been the shining jewels in the firmament of the pharma industry for almost the last two decades. They have returned billions of dollars in sales, and if their performance has not been the unalloyed triumph that was foreseen at their inception, they have, at least in some instances, produced impressive gains in patient response. Today they are one of the most fundamental strategies for treating patients with hematological malignancies and solid tumors. This report explores the next level of therapy, combining antibodies with additional agents.

[InsightPharmaReports.com/Combination-Antibody-Therapy-Report](http://InsightPharmaReports.com/Combination-Antibody-Therapy-Report)

---

### Report Pricing - The Development of Therapeutic Monoclonal Antibodies Second Edition

<table>
<thead>
<tr>
<th>Pricing</th>
<th>Single User</th>
<th>Single Site</th>
<th>Multi Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price</td>
<td>$385.00</td>
<td>$1,595.00</td>
<td>$3,995.00</td>
</tr>
</tbody>
</table>

### Report Pricing - Cancer Immunotherapy: Building on Initial Successes to Improve Clinical Outcomes

<table>
<thead>
<tr>
<th>Pricing</th>
<th>Single User</th>
<th>Single Site</th>
<th>Multi Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price</td>
<td>$1,595.00</td>
<td>$3,995.00</td>
<td>$9,950.00</td>
</tr>
</tbody>
</table>

### Report Pricing - Commercializing Novel IVDs: A Comprehensive Manual for Success

<table>
<thead>
<tr>
<th>Pricing</th>
<th>Electronic PDF</th>
<th>Print Copy</th>
<th>PDF/Print</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price</td>
<td>$695.00</td>
<td>$795.00</td>
<td>$895.00</td>
</tr>
</tbody>
</table>

### Report Pricing - Combination Antibody Therapy for Cancer Treatment Overview

<table>
<thead>
<tr>
<th>Pricing</th>
<th>Academic/GVT Single User</th>
<th>Single User</th>
<th>Single Site</th>
<th>Multi Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price</td>
<td>$1,595.00</td>
<td>$2,495.00</td>
<td>$3,995.00</td>
<td>$9,950.00</td>
</tr>
</tbody>
</table>
**Patient Enrollment and Recruitment Market Study**

Insight Pharma Reports Patient Enrollment & Recruitment Market Study surveyed 100 clinical trial professionals on:
- Enrollment Challenges
- Mobile Technologies and BYOD
- Patient Engagement
- Technologies that Run Trials

[InsightPharmaReports.com/Patient-Enrollment-Recruitment-Study](http://InsightPharmaReports.com/Patient-Enrollment-Recruitment-Study)

**Report Pricing**

Single User - $399.00

**Gene Therapy: Moving Toward Commercialization**

Insight Pharma Reports’ Gene Therapy: Moving Toward Commercialization”, outlines the progress of the gene therapy field since its inception in the 1970s, with a special focus on clinical-stage gene therapy programs that are aimed at commercialization, and the companies that are carrying out these programs. A major theme of this report is whether gene therapy can attain commercial success by the early-to-mid 2020s, which types of gene therapy programs have the greatest likelihood of success, and what hurdles might stand in the way of clinical and commercial success of leading gene therapy programs.

[InsightPharmaReports.com/Gene-Therapy-Report](http://InsightPharmaReports.com/Gene-Therapy-Report)

**Report Pricing**

Academic/GVT Single User - $1,595.00
Single User - $2,495.00
Single Site - $3,995.00
Multi Site - $9,950.00

**The Human Microbiome: Advancing New Frontiers in a Rapidly Emerging Market**

This report focuses on biomedical aspects of research, development, and commercial endeavors in the human microbiome space. It includes essential background information, evolution of the field, advances in basic research, events in the emerging commercial market, deal activity, interviews with experts, and trends in microbiome research and commerce. Primary sources of information for this report include the scientific literature, discussions with experts, and an online survey of individuals working in this space.

[InsightPharmaReports.com/Human-Microbiome-2016-Report](http://InsightPharmaReports.com/Human-Microbiome-2016-Report)

**Report Pricing**

Academic/GVT Single User - $1,595.00
Single User - $2,495.00
Single Site - $3,995.00
Multi Site - $9,950.00

**Marketing to Life Scientists: Second Edition**

As marketers, we all have the same struggles – whether it is not being able to get our messages in front of our customers or prospects or not delivering enough leads to our sales team, we all share a common struggle – a marketer’s job is not getting easier.

The Second Edition of the Marketing for Life Scientists: Best Practices Guide for Marketers is an informative tool for marketers that surveyed over 600 life scientists asking the questions that can marketers tailor their efforts more strategically towards their target market.

[InsightPharmaReports.com/Marketing-To-Life-Scientists-2016](http://InsightPharmaReports.com/Marketing-To-Life-Scientists-2016)

**Report Pricing**

Academic/GVT Single User - $995.00
Single User - $1,595.00
Single Site - $2,995.00
Multi Site - $3,950.00

**Biomanufacturing Capacity Strategies: Developing a Flexible, Scalable and Lean Biomanufacturing System**

This report focuses on the need for a more reactive and dynamic biomanufacturing approach than is the current industry standard.

[InsightPharmaReports.com/Biomanufacturing-Capacity-Strategies-Report](http://InsightPharmaReports.com/Biomanufacturing-Capacity-Strategies-Report)

**Report Pricing**

Academic/GVT Single User - $1,095.00
Single User - $1,995.00
Single Site - $3,495.00
Multi Site - $9,550.00

**Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management**

This report explores the background, history and basic research of liquid biopsy covering the three sample categories that dominate liquid biopsy today: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs, also known as exosomes). This report also details the commercial aspects, market dynamics, and trends of liquid biopsy.

[InsightPharmaReports.com/liquid-biopsy-report](http://InsightPharmaReports.com/liquid-biopsy-report)

**Report Pricing**

Academic/GVT Single User - $1,595.00
Single User - $2,495.00
Single Site - $3,995.00
Multi Site - $9,950.00
Marketing to Life Scientists: A Best Practice Guide for Marketers

Over 500 active life scientists across Biotech, Pharma, Academic, Healthcare, Hospital, Government and CRO industries answer questions and provide insight to marketers. The report is laid out with commentary, analysis and striking visuals divided into key categories, including: Technology and Mobile, Outbound Marketing, Email Marketing, Telemarketing, Direct Mail Marketing, Social Media, Content Marketing, Advertising Mediums, Tradeshows and Other Media.

The Human Microbiome: Biomedical Implications and Birth of a Market

This report covers the evolution of microbiome research and its growth in the commercial market. Specific areas of study include microbial ecology, systems biology, diet, diagnostics, contributions in health and disease, and infectious disease.

Cancer Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, and Adoptive T-cell Therapies

This report focuses on the rising potential for the newest and most promising of cancer treatments: cancer immunotherapy. It will cover the following principle therapies; checkpoint inhibitors, anticancer vaccines, and adoptive cellular immunotherapy.

Biomarkers: Discovery and Development for a Diagnostic Approach to Neurodegenerative Disorders

Including substantial background information, illustrated with graphics and figures, this report captures market growth of biomarkers, advantages, disadvantages, and validation techniques.

Antibiotic Renaissance: Technology and Market Advances in the War against Drug-resistant Bacteria

This report covers evolutionary growth of antibiotic resistant bacteria with a focus in research aspects, commercial aspects, market aspects, and trends in antibiotic resistance.

Vaccines: The End of Illness

This report focuses on the most recent vaccine research, emphasizing their reputation as an unmatched tool of efficient healthcare. Their low cost, extended protection and the impossibility of their circumvention through development of resistance on the part of the target pathogen have been longstanding attributes of vaccines. Today, vaccine technology is undergoing a fundamental revolution, taking advantage of the profound understanding of the immune system and its ability to mount protective antibody production and cell-based responses to foreign antigens. Understanding these properties will not only enable the development of innovative diagnostics but also the advancement of therapeutic applications.

InsightPharmaReports.com/marketing-to-life-scientists-guide

InsightPharmaReports.com/human-microbiome-report

InsightPharmaReports.com/cancer-immunotherapy-report

InsightPharmaReports.com/neurobiomarkers-and-diagnostics/report

InsightPharmaReports.com/drug-resistant-bacteria/

InsightPharmaReports.com/vaccines-endofillness

With an academic institution, government agency, at a non-profit or a start-up? Looking for a corporate or site license? Want to order multiple reports? Can’t find a report you are looking for?

Contact Jeff Knight at: jknight@InsightPharmaReports.com or call (781) 972-1347
Other titles available through our Affiliated Reports Collections include:

- Microfluidics Market – World Forecasts
- Evolving Pharmaceutical Marketing Strategies: Digital as a Key Component of Multichannel Marketing
- MediPoint: Respiratory Ventilators and Resuscitators
- Global Liquid Biopsy Market
- Mice Model Market by Type, Technology, Application, Service & Care Products
- Global Antibacterial Drugs Market - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance
- Global Cartilage Repair and Regeneration Market, by Treatment Modalities, by Procedure Type, by Application Outlook
- Liquid Biopsy Market: Cancer Type
- Global Liquid Biopsy Market
- Electronic Media Use in Academic Medical Center Patient Recruitment
- Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company
- Infectious Disease Tests, and Strategic Profiles of Leading Reagent and Instrument Suppliers
- PharmSource - CMO Scorecard: Outsourcing of NDA Approvals and CMO
- Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021
- CNS Lymphoma Market: By Prognosis Type
- Generic Drugs Market: By Drug Class (Cardiovascular Products, Anti-Infective Drugs)
- 2016 Molecular Blood Typing, Grouping and Infectious Disease NAT Screening
- Value Added Services: Payer Perspectives (2016)
- Market Access and Commercial Excellence in Managed Markets
- Biosimilars Education: Addressing a significant unmet need
- The Future of Medical Affairs
- Diagnostic Imaging: X-Ray, Ultrasound, CT, MRI, PACS, PET, Nuclear
- World Medical Imaging Industry: Market Segment Forecasts and Strategies of Leading Suppliers
- Digital Pathology Market by Product, Type, End User, Application - Global Forecasts
- Clinical Information System Market: By System Type; By Platform
- Nanobiotechnology Market: By Technology
- Telemedicine Technologies Market
- Patient-centric pharma: Advancing the new business model
- Global Animal Health Partnering Terms and Agreements
- Global Viral Partnering: Deal trends, players and financials
- Ocular Pain Global Clinical Trials Review
- Ophthalmic Lasers - Medical Devices Pipeline Assessment
- United States Healthcare IT Market Outlook
- North America Clinical IT Systems Market Outlook
- Global Wearable Medical Device Market Outlook
- Measuring Marketing Channel Effectiveness
- The Future of Orphan Drugs
- The Healthcare Internet of Things: A Network of Opportunities for All
- Pharma Investment in Digital Health: Strategies for success
- Powering Commercial Effectiveness Through Big Data and Analytics
- Mapping the Patient Journey: Harnessing the power of big data and analytics

For a full listing of our Affiliated Reports Collection, visit: InsightPharmaReports.com
## Bundle Packages:

New this year, Insight Pharma Reports are offering a series of bundled report packages.

<table>
<thead>
<tr>
<th><strong>Designs on the Future of Health Reports Bundle - $1,112</strong></th>
<th><strong>Ocular Pain Global API Reports Bundle - $3,700</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Designs on the Future of Health: The ambitions of Google, Apple, et al</td>
<td>• Ocular Pain-Global API Manufacturers - Marketed and Phase III Drugs Landscape</td>
</tr>
<tr>
<td>• Google’s Ambitions in Health</td>
<td>• Ocular Disorders: Rising Therapeutics, Technologies, and Devices</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>T-Cell Immunotherapy by bispecific antibodies and CAR &amp; TCR engineered T-cells Reports Bundle - $2,700</strong></th>
<th><strong>Ocular Hypertension Bundle - $3,500</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• T-Cell Redirecting Bispecific Antibodies: A competitive landscape analysis of stakeholders, technologies, pipelines and deals</td>
<td>• Ocular Hypertension - Global Clinical Trials Review</td>
</tr>
<tr>
<td>• TCR &amp; CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs</td>
<td>• Ocular Disorders: Rising Therapeutics, Technologies, and Devices</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Prenatal Diagnostics &amp; Genetic Testing Reports Bundle - $2,700</strong></th>
<th><strong>Therapeutic Antibody Reports Bundle: ADCs, Bispecifics, Biosimilars &amp; Biosuperiors Reports Bundle - $3,500</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Prenatal Diagnostic Testing</td>
<td>• Competitor Analysis: Antibody-Drug Conjugates (ADC)</td>
</tr>
<tr>
<td>• Global Prenatal and Newborn Genetic Testing Market</td>
<td>• Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies</td>
</tr>
<tr>
<td></td>
<td>• Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory &amp; Other Diseases</td>
</tr>
<tr>
<td></td>
<td>• T-Cell Redirecting Bispecific Antibodies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Prenatal Diagnostics &amp; Testing Markets Reports Bundle - $2,700</strong></th>
<th><strong>Gene Therapy Reports Bundle - $3,995</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Prenatal Diagnostic Testing</td>
<td>• Gene Therapy: Moving Toward Commercialization</td>
</tr>
<tr>
<td>• Prenatal Testing Market in the US</td>
<td>• Global Gene Therapy Partnering Terms and Agreements</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Prenatal Diagnostics &amp; US Testing Reports Bundle - $2,400</strong></th>
<th><strong>Human Microbiome Reports Bundle - $3,995</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Prenatal Diagnostic Testing</td>
<td>• The Human Microbiome: Advancing New Frontiers in a Rapidly Emerging Market</td>
</tr>
<tr>
<td>• US Non-Invasive Prenatal Testing Market Outlook</td>
<td>• The Human Microbiome: Biomedical Implications and Birth of a Market</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Prenatal Diagnostics &amp; Prenatal Screening Reports Bundle - $2,495</strong></th>
<th><strong>Global Molecular Diagnostics Reports Bundle - $3,395</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Global Prenatal Screening Partnering</td>
<td>• Molecular Diagnostic Market and Testing</td>
</tr>
<tr>
<td>• Prenatal Diagnostic Testing</td>
<td>• Global Molecular Diagnostics</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Ocular Pain Bundle - $2,250</strong></th>
<th><strong>Gene Therapy &amp; Ocular Therapeutics Reports Bundle - $3,695</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Ocular Pain-Pipeline Insights</td>
<td>• Gene Therapy: Moving Towards Commercialization</td>
</tr>
<tr>
<td>• Ocular Disorders: Rising Therapeutics, Technologies, and Devices</td>
<td>• Ocular Disorders: Rising Therapeutics, Technologies, and Devices</td>
</tr>
</tbody>
</table>

| **Ocular Inflammation Bundle - $2,250** |  |
|--------------------------------|  |
| • Ocular Inflammation-Pipeline Insights |  |
| • Ocular Disorders: Rising Therapeutics, Technologies, and Devices |  |